← Back to Screener
Cartesian Therapeutics, Inc. Common Stock (RNAC)
Price$6.92
Value ScoreF
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-10.48%
Price vs S&P 500 (4W)16.25%
VGM Score22.30
Market Capitalization$221.54M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-70.66%
Cash Flow / Share (Quarterly)$-2.71
Price vs S&P 500 (YTD)-6.36%
Net Profit Margin (TTM)-8550.65%
EPS (TTM)$-5.80
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-5.80
Revenue Growth (5Y)-29.96%
EPS (Annual)$-5.02
ROI (Annual)29.46%
Net Profit Margin (5Y Avg)-1140.15%
Cash / Share (Quarterly)$4.16
Revenue Growth QoQ (YoY)-92.91%
ROA (Last FY)-43.96%
Revenue Growth TTM (YoY)-94.93%
EBITD / Share (TTM)$-5.53
ROE (5Y Avg)-185.49%
Operating Margin (TTM)-8338.87%
Cash Flow / Share (Annual)$-3.05
P/B Ratio294.60x
P/B Ratio (Quarterly)512.19x
Net Income / Employee (Annual)$-1,737,400
EV / Revenue (TTM)57.97x
Net Interest Coverage (TTM)-0.62x
ROA (TTM)-45.09%
EPS Incl Extra (Annual)$-5.02
Current Ratio (Annual)8.65x
Quick Ratio (Quarterly)7.46x
3-Month Avg Trading Volume0.18M
52-Week Price Return-24.60%
EV / Free Cash Flow (Annual)3.02x
Revenue / Employee (TTM)$23,700
Tangible BV / Share (Quarterly)$0.39
P/S Ratio (Annual)79.21x
Asset Turnover (Annual)0.01x
52-Week High$15.57
Operating Margin (5Y Avg)-1112.90%
EPS Excl Extra (Annual)$-5.02
CapEx CAGR (5Y)46.26%
Tangible BV CAGR (5Y)12.61%
26-Week Price Return5.45%
Quick Ratio (Annual)8.45x
13-Week Price Return-9.70%
Total Debt / Equity (Annual)0.28x
Current Ratio (Quarterly)7.65x
Enterprise Value$102.90M
Revenue / Share Growth (5Y)-53.44%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-23.36%
Revenue / Employee (Annual)$37,300
Pretax Margin (Annual)-4987.31%
Cash / Share (Annual)$4.81
3-Month Return Std Dev105.65%
Net Income / Employee (TTM)$-2,023,700
ROE (Last FY)37.71%
Net Interest Coverage (Annual)-0.64x
EPS Basic Excl Extra (Annual)$-5.02
P/FCF (TTM)29.57x
Receivables Turnover (TTM)1.75x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.80
Receivables Turnover (Annual)2.82x
ROI (TTM)-3215.82%
P/S Ratio (TTM)124.81x
Pretax Margin (5Y Avg)-1216.71%
Revenue / Share (Annual)$0.11
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-52.81%
Year-to-Date Return4.58%
5-Day Price Return11.70%
EPS Normalized (Annual)$-5.02
ROA (5Y Avg)-25.70%
Net Profit Margin (Annual)-4658.63%
Month-to-Date Return21.22%
Cash Flow / Share (TTM)$-0.23
EBITD / Share (Annual)$-5.41
Operating Margin (Annual)-5127.10%
LT Debt / Equity (Annual)0.19x
ROI (5Y Avg)-74.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.80
P/TBV (Quarterly)3.57x
P/B Ratio (Annual)2.17x
Pretax Margin (TTM)-9068.56%
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)-19.45%
Beta0.70x
P/FCF (Annual)6.50x
Revenue / Share (TTM)$0.07
ROE (TTM)-3215.82%
52-Week Low$5.60
vGradeF
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.46est. -0.90
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNACCartesian Therapeutics, Inc. Common Stock | F | F | C | $6.92 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-based therapies to induce immune tolerance. The company's ImmTOR platform uses proprietary manufacturing and cellular engineering technology to mitigate unwanted immune responses, particularly in autoimmune and transplant-related conditions. This approach represents a novel mechanism for treating conditions where immune suppression needs to be targeted rather than systemic.